- Home
- KRO vs XNCR Comparison
KRO vs XNCR Comparison
Compare KRO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRO
- XNCR
- Stock Information
- Founded
- KRO 1916
- XNCR 1997
- Country
- KRO United States
- XNCR United States
- Employees
- KRO N/A
- XNCR N/A
- Industry
- KRO Major Chemicals
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- KRO Industrials
- XNCR Health Care
- Exchange
- KRO Nasdaq
- XNCR Nasdaq
- Market Cap
- KRO 1.3B
- XNCR 1.5B
- IPO Year
- KRO N/A
- XNCR 2013
- Fundamental
- Price
- KRO $11.37
- XNCR $23.07
- Analyst Decision
- KRO Hold
- XNCR Strong Buy
- Analyst Count
- KRO 3
- XNCR 8
- Target Price
- KRO $12.00
- XNCR $35.50
- AVG Volume (30 Days)
- KRO 157.1K
- XNCR 498.6K
- Earning Date
- KRO 11-06-2024
- XNCR 11-06-2024
- Dividend Yield
- KRO 1.76%
- XNCR N/A
- EPS Growth
- KRO N/A
- XNCR N/A
- EPS
- KRO 0.82
- XNCR N/A
- Revenue
- KRO $1,864,100,000.00
- XNCR $85,164,000.00
- Revenue This Year
- KRO $27.63
- XNCR N/A
- Revenue Next Year
- KRO $10.25
- XNCR $86.53
- P/E Ratio
- KRO $13.89
- XNCR N/A
- Revenue Growth
- KRO 15.87
- XNCR N/A
- 52 Week Low
- KRO $8.23
- XNCR $15.31
- 52 Week High
- KRO $14.50
- XNCR $26.84
- Technical
- Relative Strength Index (RSI)
- KRO 42.70
- XNCR 62.73
- Support Level
- KRO $11.20
- XNCR $23.05
- Resistance Level
- KRO $12.98
- XNCR $24.04
- Average True Range (ATR)
- KRO 0.43
- XNCR 0.83
- MACD
- KRO -0.07
- XNCR 0.10
- Stochastic Oscillator
- KRO 11.54
- XNCR 68.65
About KRO Kronos Worldwide Inc
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in a variety of products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second-largest product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.